Aranesp Side Effects. Aranesp (generic: darbepoetin alfa) is approved to treat anemia caused by chemotherapy. Anemia is a common side effect of chemotherapy, which can damage the production of red blood cells.
In anemia, the blood is lacking in healthy red blood cells, which transport oxygen to organs. The FDA approved Aranesp on September 17, 2001.
On January 14, 2005 Amgen and the FDA sent letters to doctors advising them of a revision to the warning label for Aranesp.
Two new studies with other drugs in the same class of Aranesp
Two new studies with other drugs in the same class of Aranesp, known as erythropoietic drugs, have shown that using the drugs at higher-than-recommended doses increases the risk of adverse effects including blood clots and death.
Other life threatening side effects of Aranesp include cardiac arrest, hypertension, vascular thrombosis and convulsions.
Although the studies were conducted with other drugs (Eprex and NeoRecormon), Amgen has incorporated this information into the prescribing information for Aranesp to alert doctors to these potential risks.